Paola León-Mimila1, Hugo Villamil-Ramírez1, Luis R Macías-Kauffer1,2, Leonor Jacobo-Albavera3, Blanca E López-Contreras1, Rosalinda Posadas-Sánchez4, Carlos Posadas-Romero4, Sandra Romero-Hidalgo5, Sofía Morán-Ramos1,6, Mayra Domínguez-Pérez3, Marisol Olivares-Arevalo1, Priscilla López-Montoya1, Roberto Nieto-Guerra1, Víctor Acuña-Alonzo7, Gastón Macín-Pérez7, Rodrigo Barquera-Lozano8, Blanca E Del-Río-Navarro9, Israel González-González10, Francisco Campos-Pérez10, Francisco Gómez-Pérez11, Victor J Valdés12, Alicia Sampieri12, Juan G Reyes-García13, Miriam Del C Carrasco-Portugal14, Francisco J Flores-Murrieta13,14, Carlos A Aguilar-Salinas11,15, Gilberto Vargas-Alarcón16, Diana Shih17, Peter J Meikle18, Anna C Calkin19,20,21, Brian G Drew19,20,21, Luis Vaca12, Aldons J Lusis17, Adriana Huertas-Vazquez17, Teresa Villarreal-Molina3, Samuel Canizales-Quinteros1. 1. Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.). 2. Dirección de Planeación, Enseñanza e Investigación, Hospital Regional de Alta Especialidad de Ixtapaluca, Estado de México (L.R.M.-K.). 3. Laboratorio de Enfermedades Cardiovasculares, INMEGEN, Mexico City (L.J.-A., M.D.-P., T.V.-M.). 4. Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City (R.P.-S., C.P.-R.). 5. Departamento de Genómica Computacional, INMEGEN, Mexico City (S.R.-H.). 6. Consejo Nacional de Ciencia y Tecnología (CONACyT), Mexico City (S.M.-R.). 7. Escuela Nacional de Antropología e Historia, Mexico City (V.A.-A., G.M.-P.). 8. Max Planck Institute for the Science of Human History, Jena, Germany (R.B.-L.). 9. Hospital Infantil de México Federico Gómez, Mexico City (B.E.D.-R.-N.). 10. Hospital General Rubén Leñero, Mexico City (I.G.-G., F.C.-P.). 11. Unidad de Investigación en Enfermedades Metabólicas and Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (F.G.-P., C.A.A.-S.). 12. Instituto de Fisiología Celular, UNAM, Mexico City (V.J.V., A.S., L.V.). 13. Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City (J.G.R.-G., F.J.F.-M.). 14. Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City (M.C.-P., F.J.F.-M.). 15. Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, N.L. Mexico (C.A.A.-S.). 16. Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City (G.V.-A.). 17. Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (D.S., A.J.L., A.H.-V.). 18. Head Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (P.J.M.). 19. Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (A.C.C., B.G.D.). 20. Central Clinical School, Monash University, Melbourne, VIC, Australia (A.C.C., B.G.D.). 21. Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, VIC, Australia (A.C.C., B.G.D.).
Abstract
Objective: Low HDL-C (high-density lipoprotein cholesterol) is the most frequent dyslipidemia in Mexicans, but few studies have examined the underlying genetic basis. Our purpose was to identify genetic variants associated with HDL-C levels and cardiovascular risk in the Mexican population. Approach and Results: A genome-wide association studies for HDL-C levels in 2335 Mexicans, identified four loci associated with genome-wide significance: CETP, ABCA1, LIPC, and SIDT2. The SIDT2 missense Val636Ile variant was associated with HDL-C levels and was replicated in 3 independent cohorts (P=5.9×10−18 in the conjoint analysis). The SIDT2/Val636Ile variant is more frequent in Native American and derived populations than in other ethnic groups. This variant was also associated with increased ApoA1 and glycerophospholipid serum levels, decreased LDL-C (low-density lipoprotein cholesterol) and ApoB levels, and a lower risk of premature CAD. Because SIDT2 was previously identified as a protein involved in sterol transport, we tested whether the SIDT2/Ile636 protein affected this function using an in vitro site-directed mutagenesis approach. The SIDT2/Ile636 protein showed increased uptake of the cholesterol analog dehydroergosterol, suggesting this variant affects function. Finally, liver transcriptome data from humans and the Hybrid Mouse Diversity Panel are consistent with the involvement of SIDT2 in lipid and lipoprotein metabolism. Conclusions: This is the first genome-wide association study for HDL-C levels seeking associations with coronary artery disease in the Mexican population. Our findings provide new insight into the genetic architecture of HDL-C and highlight SIDT2 as a new player in cholesterol and lipoprotein metabolism in humans.
Objective: Low HDL-C (high-density lipoprotein cholesterol) is the most frequent dyslipidemia in Mexicans, but few studies have examined the underlying genetic basis. Our purpose was to identify genetic variants associated with HDL-C levels and cardiovascular risk in the Mexican population. Approach and Results: A genome-wide association studies for HDL-C levels in 2335 Mexicans, identified four loci associated with genome-wide significance: CETP, ABCA1, LIPC, and SIDT2. The SIDT2 missense Val636Ile variant was associated with HDL-C levels and was replicated in 3 independent cohorts (P=5.9×10−18 in the conjoint analysis). The SIDT2/Val636Ile variant is more frequent in Native American and derived populations than in other ethnic groups. This variant was also associated with increased ApoA1 and glycerophospholipid serum levels, decreased LDL-C (low-density lipoprotein cholesterol) and ApoB levels, and a lower risk of premature CAD. Because SIDT2 was previously identified as a protein involved in sterol transport, we tested whether the SIDT2/Ile636 protein affected this function using an in vitro site-directed mutagenesis approach. The SIDT2/Ile636 protein showed increased uptake of the cholesterol analog dehydroergosterol, suggesting this variant affects function. Finally, liver transcriptome data from humans and the Hybrid Mouse Diversity Panel are consistent with the involvement of SIDT2 in lipid and lipoprotein metabolism. Conclusions: This is the first genome-wide association study for HDL-C levels seeking associations with coronary artery disease in the Mexican population. Our findings provide new insight into the genetic architecture of HDL-C and highlight SIDT2 as a new player in cholesterol and lipoprotein metabolism in humans.
Authors: Andreas Teufel; Timo Itzel; Wiebke Erhart; Mario Brosch; Xiao Yu Wang; Yong Ook Kim; Witigo von Schönfels; Alexander Herrmann; Stefan Brückner; Felix Stickel; Jean-François Dufour; Triantafyllos Chavakis; Claus Hellerbrand; Rainer Spang; Thorsten Maass; Thomas Becker; Stefan Schreiber; Clemens Schafmayer; Detlef Schuppan; Jochen Hampe Journal: Gastroenterology Date: 2016-06-16 Impact factor: 22.682
Authors: Anatole Ghazalpour; Brian Bennett; Vladislav A Petyuk; Luz Orozco; Raffi Hagopian; Imran N Mungrue; Charles R Farber; Janet Sinsheimer; Hyun M Kang; Nicholas Furlotte; Christopher C Park; Ping-Zi Wen; Heather Brewer; Karl Weitz; David G Camp; Calvin Pan; Roumyana Yordanova; Isaac Neuhaus; Charles Tilford; Nathan Siemers; Peter Gargalovic; Eleazar Eskin; Todd Kirchgessner; Desmond J Smith; Richard D Smith; Aldons J Lusis Journal: PLoS Genet Date: 2011-06-09 Impact factor: 5.917
Authors: Mariaelisa Graff; Leslie S Emery; Anne E Justice; Esteban Parra; Jennifer E Below; Nicholette D Palmer; Chuan Gao; Qing Duan; Adan Valladares-Salgado; Miguel Cruz; Alanna C Morrison; Eric Boerwinkle; Eric A Whitsel; Charles Kooperberg; Alex Reiner; Yun Li; Carlos Jose Rodriguez; Gregory A Talavera; Carl D Langefeld; Lynne E Wagenknecht; Jill M Norris; Kent D Taylor; George Papanicolaou; Eimear Kenny; Ruth J F Loos; Yii-Der Ida Chen; Cathy Laurie; Tamar Sofer; Kari E North Journal: Lipids Health Dis Date: 2017-10-12 Impact factor: 3.876
Authors: Phuwanat Sakornsakolpat; Dmitry Prokopenko; Brian D Hobbs; Michael H Cho; Maxime Lamontagne; Nicola F Reeve; Anna L Guyatt; Victoria E Jackson; Nick Shrine; Dandi Qiao; Traci M Bartz; Deog Kyeom Kim; Mi Kyeong Lee; Jeanne C Latourelle; Xingnan Li; Jarrett D Morrow; Ma'en Obeidat; Annah B Wyss; Per Bakke; R Graham Barr; Terri H Beaty; Steven A Belinsky; Guy G Brusselle; James D Crapo; Kim de Jong; Dawn L DeMeo; Tasha E Fingerlin; Sina A Gharib; Amund Gulsvik; Ian P Hall; John E Hokanson; Woo Jin Kim; David A Lomas; Stephanie J London; Deborah A Meyers; George T O'Connor; Stephen I Rennard; David A Schwartz; Pawel Sliwinski; David Sparrow; David P Strachan; Ruth Tal-Singer; Yohannes Tesfaigzi; Jørgen Vestbo; Judith M Vonk; Jae-Joon Yim; Xiaobo Zhou; Yohan Bossé; Ani Manichaikul; Lies Lahousse; Edwin K Silverman; H Marike Boezen; Louise V Wain; Martin D Tobin Journal: Nat Genet Date: 2019-02-25 Impact factor: 38.330
Authors: Thomas Grenier-Larouche; Lydia Coulter Kwee; Yann Deleye; Paola Leon-Mimila; Jacquelyn M Walejko; Robert W McGarrah; Simon Marceau; Sylvain Trahan; Christine Racine; André C Carpentier; Aldons J Lusis; Olga Ilkayeva; Marie-Claude Vohl; Adriana Huertas-Vazquez; André Tchernof; Svati H Shah; Christopher B Newgard; Phillip J White Journal: JCI Insight Date: 2022-08-08